Candel Therapeutics Inc CADL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $10.16
- Day Range
- $10.03–10.37
- 52-Week Range
- $4.35–14.00
- Bid/Ask
- $10.20 / $10.30
- Shares Outstanding
- 76.52M
- Market Cap
- $778.96M
- Volume/Avg
- 878,803 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 55
- Website
- https://www.candeltx.com
Valuation
|
Metric
|
CADL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CADL
|
|---|---|
Quick Ratio | 15.89 |
Current Ratio | 16.09 |
Interest Coverage | −18.84 |
Quick Ratio
CADL
Profitability
|
Metric
|
CADL
|
|---|---|
Return on Assets (Normalized) | −43.86% |
Return on Equity (Normalized) | −66.26% |
Return on Invested Capital (Normalized) | −49.86% |
Return on Assets
CADL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|v!tWPV | LOCK|l>nd | $128B | |||
| Moderna Inc
MRNA
| LOCK|CPTWcN | LOCK|x% | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vPv&M> | LOCK|sdDw | $76B | |||
| argenx SE ADR
ARGX
| LOCK|hm<JHj | LOCK|^@q | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#<qXrF | LOCK|P# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$jz^>@ | LOCK|@!#<< | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#HVJqjst | LOCK|D>%!q | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|NP@QN^$ | LOCK|?vc | $24B | |||
| Incyte Corp
INCY
| LOCK|GWCVd#H | LOCK|<hY | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|T#%^csS | LOCK|qd | $15B |
United States